{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:11:50Z","timestamp":1758039110828,"version":"3.44.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ad.2016.07.007","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T20:10:12Z","timestamp":1472847012000},"page":"184-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enfermedad inflamatoria intestinal: abordaje conjunto digestivo-dermatol\u00f3gico"],"prefix":"10.1016","volume":"108","author":[{"given":"M.A.","family":"S\u00e1nchez-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Garcia-Planella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Laiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2016.07.007_bib0285","first-page":"294","article-title":"The history of genetics in inflammatory bowel disease","volume":"27","author":"Ek","year":"2014","journal-title":"Ann Gastroenterol."},{"key":"10.1016\/j.ad.2016.07.007_bib0290","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.ad.2016.07.007_bib0295","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ad.2012.11.006","article-title":"The pathogenesis and genetics of psoriasis","volume":"105","author":"Puig","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2016.07.007_bib0300","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/gut.2006.116467","article-title":"Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease","volume":"56","author":"Kugathasan","year":"2007","journal-title":"Gut."},{"key":"10.1016\/j.ad.2016.07.007_bib0305","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2036.2009.04209.x","article-title":"Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients","volume":"31","author":"Veny","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ad.2016.07.007_bib0310","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","article-title":"Inflammatory bowel disease and mutations affecting the interleukin-10 receptor","volume":"361","author":"Glocker","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2016.07.007_bib0315","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015354","article-title":"Psoriasis","volume":"4","author":"Di Meglio","year":"2014","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/j.ad.2016.07.007_bib0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.det.2014.09.001","article-title":"Genetics of psoriasis","volume":"33","author":"Mahil","year":"2015","journal-title":"Dermatol Clin."},{"key":"10.1016\/j.ad.2016.07.007_bib0325","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature."},{"key":"10.1016\/j.ad.2016.07.007_bib0330","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2016.07.007_bib0335","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology."},{"key":"10.1016\/j.ad.2016.07.007_bib0340","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracelular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J Immunol."},{"key":"10.1016\/j.ad.2016.07.007_bib0345","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: Toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2016.07.007_bib0350","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjd.12331","article-title":"Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B\/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12\/23 blocker ustekinumab","volume":"169","author":"Talamonti","year":"2013","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2016.07.007_bib0355","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4065\/81.11.1462","article-title":"Smoking and inflammatory bowel disease: A meta-analysis","volume":"81","author":"Mahid","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.ad.2016.07.007_bib0360","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/ajg.2010.398","article-title":"Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease","volume":"105","author":"Shaw","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.ad.2016.07.007_bib0365","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/ajg.2010.252","article-title":"The inflammatory bowel diseases and ambient air pollution: A novel association","volume":"105","author":"Kaplan","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.ad.2016.07.007_bib0370","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/ibd.21455","article-title":"Ambient air pollution correlates with hospitalizations for inflammatory bowel disease: An ecologic analysis","volume":"17","author":"Ananthakrishnan","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.ad.2016.07.007_bib0375","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/jn\/130.11.2648","article-title":"1,25-dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease","volume":"130","author":"Cantorna","year":"2000","journal-title":"J Nutr."},{"key":"10.1016\/j.ad.2016.07.007_bib0380","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1365-2036.2010.04463.x","article-title":"Vitamin D3 treatment of Crohn's disease patients increases stimulated T cell IL-6 production and proliferation","volume":"32","author":"Bendix-Struve","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ad.2016.07.007_bib0385","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10787-013-0197-1","article-title":"Oral vitamin D3 supplementation reduces monocyte-derived dendritic cell maturation and cytokine production in Crohn's disease patients","volume":"22","author":"Bartels","year":"2014","journal-title":"Inflammopharmacology."},{"key":"10.1016\/j.ad.2016.07.007_bib0390","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2004.04.061","article-title":"High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease","volume":"127","author":"Darfeuille-Michaud","year":"2004","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ad.2016.07.007_bib0395","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2004.03.054","article-title":"Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer","volume":"127","author":"Martin","year":"2004","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ad.2016.07.007_bib0400","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/labinvest.3700661","article-title":"Invasive Escherichia coli are a feature of Crohn's disease","volume":"87","author":"Sasaki","year":"2007","journal-title":"Lab Invest."},{"key":"10.1016\/j.ad.2016.07.007_bib0405","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory comensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ad.2016.07.007_bib0410","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/ibd.20903","article-title":"Low counts of Faecali bacterium prausnitzii in colitis microbiota","volume":"15","author":"Sokol","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.ad.2016.07.007_bib0415","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2011.27","article-title":"Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment","volume":"106","author":"Arijs","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.ad.2016.07.007_bib0420","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/exd.12572","article-title":"Psoriasis is not an autoimmune disease?","volume":"24","author":"Fry","year":"2015","journal-title":"Exp Dermatol."},{"key":"10.1016\/j.ad.2016.07.007_bib0425","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/rheumatology\/ket319","article-title":"The bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: Challenges and opportunities offered by recent technological advances","volume":"53","author":"Castelino","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ad.2016.07.007_bib0430","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jbi.2014.08.012","article-title":"Evaluation of matched control algorithms in EHR-based phenotyping studies: A case study of inflammatory bowel disease comorbidities","volume":"52","author":"Castro","year":"2014","journal-title":"J Biomed Inform."},{"key":"10.1016\/j.ad.2016.07.007_bib0435","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/ajg.2009.454","article-title":"Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease","volume":"104","author":"Toedter","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.ad.2016.07.007_bib0440","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","article-title":"Obesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications","volume":"105","author":"Carrascosa","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2016.07.007_bib0445","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1365-2133.2011.10526.x","article-title":"Smoking and pathogenesis of psoriasis: A review of oxidative, inflammatory and genetic mechanisms","volume":"165","author":"Armstrong","year":"2011","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2016.07.007_bib0450","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/2050640613487194","article-title":"Fistulizing Crohn's disease: Diagnosis and management","volume":"1","author":"Gecse","year":"2013","journal-title":"United European Gastroenterol J."},{"key":"10.1016\/j.ad.2016.07.007_bib0455","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/2015\/852723","article-title":"Clinicians\u2019 guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease","volume":"29","author":"Bressler","year":"2015","journal-title":"Can J Gastroenterol Hepatol."},{"key":"10.1016\/j.ad.2016.07.007_bib0460","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ad.2016.07.007_bib0465","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: A systematic literature review based on 222 cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ad.2016.07.007_bib0470","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut."},{"key":"10.1016\/j.ad.2016.07.007_bib0475","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1365-2036.2012.05082.x","article-title":"Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease","volume":"35","author":"Buisson","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ad.2016.07.007_bib0480","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/jgh.12352","article-title":"Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease","volume":"29","author":"Ampuero","year":"2014","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.ad.2016.07.007_bib0485","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/ibd.20942","article-title":"Musculoskeletal manifestations of inflammatory bowel disease","volume":"15","author":"Bourikas","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.ad.2016.07.007_bib0490","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2165\/11638120-000000000-00000","article-title":"Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease","volume":"72","author":"Trikudanathan","year":"2012","journal-title":"Drugs."},{"key":"10.1016\/j.ad.2016.07.007_bib0495","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/ard.2009.110767","article-title":"Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: A consensual approach by the ASAS\/OMERACT MRI group","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2016.07.007_bib0500","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.ad.2016.07.007_bib0505","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00228-009-0719-3","article-title":"Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatorydrugs: Myth or reality?","volume":"65","author":"Kefalakes","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ad.2016.07.007_bib0510","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","article-title":"Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study","volume":"42","author":"Clegg","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ad.2016.07.007_bib0515","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.crohns.2009.11.005","article-title":"The joint-gut axis in inflammatory bowel diseases","volume":"4","author":"Brakenhoff","year":"2010","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ad.2016.07.007_bib0520","first-page":"24","article-title":"Treatment of ankylosing spondylitis","volume":"78","author":"Clegg","year":"2006","journal-title":"J Rheumatol Suppl."},{"key":"10.1016\/j.ad.2016.07.007_bib0525","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00124743-200104000-00002","article-title":"Crohn's disease arthritis treated with infliximab: An open trial in four patients","volume":"7","author":"Ellman","year":"2001","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.ad.2016.07.007_bib0530","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1111\/j.1572-0241.2002.06064.x","article-title":"Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease","volume":"97","author":"Herfarth","year":"2002","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.ad.2016.07.007_bib0535","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ad.2016.07.007_bib0540","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ad.2016.07.007_bib0545","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2016.07.007_bib0550","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.crohns.2013.11.019","article-title":"Risk factors of work disability in patients with inflammatory bowel disease--A Dutch nationwide web-based survey: Work disability in inflammatory bowel disease","volume":"8","author":"Van der Valk","year":"2014","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.ad.2016.07.007_bib0555","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn's disease digestive damage score, the L\u00e9mann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.ad.2016.07.007_bib0560","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ad.2013.04.003","article-title":"Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731016302708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731016302708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:06:16Z","timestamp":1757552776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731016302708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0001731016302708"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2016.07.007","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfermedad inflamatoria intestinal: abordaje conjunto digestivo-dermatol\u00f3gico","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2016.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}